This suggests that the corticostriatal pool of non-heteromerizing A2AR and CB1R would be the main target of adenosinergic and cannabinergic drugs aimed at relieving the symptoms of HD at late stages, whereas the MSN pool of A2AR-CB1R heteromers could be an additional target of those drugs at early disease stages. This evidence concerns the gene ADORA2A and Huntington disease.